Literature DB >> 10738222

Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes.

F J Hoebers1, J H Borger, A A Hart, J L Peterse, E J Th, J V Lebesque.   

Abstract

BACKGROUND: The objective of the current study was to evaluate the effectiveness and morbidity of primary axillary radiotherapy in breast-conserving therapy for postmenopausal, clinically axillary lymph node negative patients with early stage breast carcinoma.
METHODS: Between 1983-1997, 105 patients with clinically negative axillary lymph nodes and breast carcinoma were treated with wide local excision followed by radiotherapy to the breast, and axillary and supraclavicular lymph node areas. Adjuvant treatment with tamoxifen was given to 75 patients. The median follow-up of patients still alive was 41 months (range, 8-137 months). Fifty-five patients with no evidence of disease at last follow-up were examined prospectively with respect to late functional damage.
RESULTS: The mean age of the patients was 64 years. Three patients developed a local recurrence. No isolated axillary lymph node recurrence was observed. In two patients, axillary recurrence was accompanied by distant metastases. The 5-year disease free interval and the overall survival were 82% (standard error [SE], 6%) and 83% (SE, 6%), respectively. In five patients, arm edema was reported and impaired shoulder function was reported in seven patients. Prospectively scored, arm edema was reported subjectively by the patient in 4% and objectively measured in 11% of cases. Impaired shoulder function was reported subjectively in 35% and objectively measured in 17% of cases. No brachial plexus neuropathy was noted.
CONCLUSIONS: Primary axillary radiotherapy for postmenopausal women with clinically lymph node negative, early stage breast carcinoma was found to result in low axillary lymph node recurrence rates with only limited late complications. Therefore, primary axillary radiotherapy should be considered as axillary treatment in selected patients as an alternative to axillary lymph node dissection. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738222     DOI: 10.1002/(sici)1097-0142(20000401)88:7<1633::aid-cncr18>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  MRI sequences for the detection of individual lymph nodes in regional breast radiotherapy planning.

Authors:  Tristan C F van Heijst; Bram van Asselen; Ruud M Pijnappel; Marissa Cloos-van Balen; Jan J W Lagendijk; Desirée van den Bongard; Mariëlle E P Philippens
Journal:  Br J Radiol       Date:  2016-05-10       Impact factor: 3.039

2.  Axillary Irradiation as an Imperative Alternative to Axillary Dissection in Clinically Lymph Node-Negative but Sentinel Node-Positive Breast Cancer Patients?

Authors:  Mirko Nitsche; Robert Hermann
Journal:  Breast Care (Basel)       Date:  2011-10-31       Impact factor: 2.860

3.  Postlumpectomy focal brachytherapy for simultaneous treatment of surgical cavity and draining lymph nodes.

Authors:  Brian A Hrycushko; Shihong Li; Chengyu Shi; Beth Goins; Yaxi Liu; William T Phillips; Pamela M Otto; Ande Bao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-23       Impact factor: 7.038

4.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.

Authors:  Mila Donker; Geertjan van Tienhoven; Marieke E Straver; Philip Meijnen; Cornelis J H van de Velde; Robert E Mansel; Luigi Cataliotti; A Helen Westenberg; Jean H G Klinkenbijl; Lorenzo Orzalesi; Willem H Bouma; Huub C J van der Mijle; Grard A P Nieuwenhuijzen; Sanne C Veltkamp; Leen Slaets; Nicole J Duez; Peter W de Graaf; Thijs van Dalen; Andreas Marinelli; Herman Rijna; Marko Snoj; Nigel J Bundred; Jos W S Merkus; Yazid Belkacemi; Patrick Petignat; Dominic A X Schinagl; Corneel Coens; Carlo G M Messina; Jan Bogaerts; Emiel J T Rutgers
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

5.  Quantifying radiation dose delivered to individual shoulder muscles during breast radiotherapy.

Authors:  David B Lipps; Sean Sachdev; Jonathan B Strauss
Journal:  Radiother Oncol       Date:  2017-01-24       Impact factor: 6.280

6.  Supraclavicular failure after breast-conserving therapy in patients with four or more positive axillary lymph nodes when prophylactic supraclavicular irradiation is omitted.

Authors:  Yasushi Hamamoto; Masaaki Kataoka; Takatoshi Semba; Kotaro Uwatsu; Yoshifumi Sugawara; Takeshi Inoue; Shinya Sakai; Shoji Aono; Tadaaki Takahashi; Shogo Oda
Journal:  Jpn J Radiol       Date:  2009-06-25       Impact factor: 2.374

7.  Regional radiotherapy versus an axillary lymph node dissection after lumpectomy: a safe alternative for an axillary lymph node dissection in a clinically uninvolved axilla in breast cancer. A case control study with 10 years follow up.

Authors:  Patty H Spruit; Sabine Siesling; Marloes A G Elferink; Ernest J A Vonk; Carel J M Hoekstra
Journal:  Radiat Oncol       Date:  2007-10-30       Impact factor: 3.481

8.  Axillary radiotherapy: an alternative treatment option for adjuvant axillary management of breast cancer.

Authors:  Jie Zhang; Chuan Wang
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

9.  Can axillary radiotherapy replace axillary dissection for patients with positive sentinel nodes? A systematic review and meta-analysis.

Authors:  Min Zhao; Wei-Guang Liu; Lei Zhang; Zi-Ning Jin; Zhan Li; Cheng Liu; Dong-Bao Li; Ying Ma; Jing-Wen Zhang; Feng Jin; Bo Chen
Journal:  Chronic Dis Transl Med       Date:  2017-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.